The role of glycolysis in tumor progression and the central role of c-Myc in glycolysis and cancer have led to an increased interest in selective targeted therapy for tumor glucose metabolism disorders and c-Myc deregulation. This evidence concerns the gene MYC and glucose metabolism disease.